Analyse TransMedics Group, Inc. (TMDX) — Kairos Score 68/100

À propos de TransMedics Group, Inc.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

2 transactions — 1 achats et 0 ventes déclarés par les dirigeants de TransMedics Group, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur TMDX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur TMDX.

• TransMedics Group (TMDX) Stock Looks Below Fair Value On Earnings
• TransMedics Group (TMDX) Could Be 19% Undervalued If Its Growth Narrative Holds

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.